XCISION MEDICAL SYSTEMS:
Fast Facts

Xcision Medical Systems, LLC (Columbia, MD) is a medical technology company that has developed a patent-protected device that provides superior breast cancer radiation treatment that is more cost-effective, efficient and patient friendly than existing options.

XCISION MEDICAL SYSTEMS:
Today’s Real Clinical Challenges

More than 2.1 million women are diagnosed with invasive breast cancer each year worldwide.

Most (2/3rd in the US) are early stage, localized disease thanks to awareness
and improved screening.

 

The standard of treatment for localized disease is surgery followed by 4-8 weeks of healing and 3-7 weeks of radiation.

Such invasive and protracted courses of care are increasingly considered by leading experts to be "overtreatment" of these patients given the prolonged and overly aggressive treatment experience.

The side effects, such as increased cardiac events from radiation and poor cosmetic                                                          results, lessen patients' quality of life.

XCISION MEDICAL SYSTEMS:
GammaPod: An Optimized Solution

Xcision Medical Systems, LLC. solves these problems with the GammaPod system, which offers a patented radiosurgery device and a patented vacuum-assisted breast immobilization device.

Radiosurgery has been used for brain cancers for decades with unsurpassed results. It has never been applied to breast cancer because there is no device that can immobilize the breast as well as the head and focus the radiation beams to the tumor in the breast.  

For the first time, we can deliver a focused dose to the tumor in the breast completely noninvasively with high precision, low toxicity and the potential for improved cosmetic outcomes. Treatments can now be completed in 1 to 5 sessions within a week.

It is also possible to replace both surgery and postoperative radiation with a single GammaPod treatment.

XCISION MEDICAL SYSTEMS:
Traction & Accomplishments

Our product development speaks for itself:

XCISION MEDICAL SYSTEMS:
Early Praise

Experts:
In the most authoritative scientific journal in radiotherapy, The International Journal of Radiation Oncology, Biology, Physics, the editorial board made a comment on one of the papers published on GammaPod: “The authors conclude that GammaPod allows adequate and more uniform dose coverage to centrally and peripherally located targets, with acceptable dose falloff and lower relative skin dose than the brachytherapy techniques considered.”

FDA:
In a press please on Dec. 22, 2017, the Deputy Director for Radiological Health at the FDA said: “With today’s clearance, patients will have access to a treatment option that provides greater accuracy in delivering radiation therapy to breast tumors while saving the surrounding breast tissue.”

Customers:
Both UT Southwestern Medical Center and the University of Maryland Medical System issued several press releases on the successful use of GammaPod system.

News Media:

CBS New York, NBC Dallas and nationally syndicated TV program The Doctors  all ran features on GammaPod.  

Patients:
All patients treated with the GammaPod are happy with their decision. At the University of Maryland Medical Center, more than 60% of all patients treated on GammaPod were self-referred from outside the health systems’ region.

Partnerships:
A GammaPod clinical consortium of 6 leading cancer treatment centers in the world has been formed. The consortium is sponsored by Xcision.

XCISION MEDICAL SYSTEMS:
Meet the Team